🇺🇸 FDA
Pipeline program

CRN09682

CRN09682-191

Phase 2 small_molecule active

Quick answer

CRN09682 for SST2-positive Neuroendocrine Neoplasms is a Phase 2 program (small_molecule) at Crinetics Pharmaceuticals with 1 ClinicalTrials.gov record(s).

Program details

Company
Crinetics Pharmaceuticals
Indication
SST2-positive Neuroendocrine Neoplasms
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials